Upcoming Class Action Notice for Actinium Pharmaceuticals Shareholders
The Gross Law Firm has issued a significant notice for shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This notice pertains to individuals who may have purchased shares during a specified class period and encourages them to reach out regarding potential participation in a class action lawsuit.
Important Class Action Details
Shareholders of ATNM are invited to explore their options for potential recovery. Those interested in filing a claim can do so even if they are not appointed as lead plaintiffs. It is important for especially those who acquired shares within the relevant time frame to make their voices heard.
Class Period and Allegations
The class period for this action spans from October 31, 2022, to August 2, 2024. The allegations indicate that the defendants may have issued misleading statements regarding the company’s Phase 3 Sierra trial data, which are essential for obtaining the FDA's approval of their targeted radiotherapy, Iomab-B BLA. Such misleading information raises concerns about the integrity of the data presented to both shareholders and regulatory bodies.
Deadline for Participation
It is imperative for potential claimants to be aware of the upcoming deadline on May 27, 2025. This timeline stresses the urgency for shareholders, prompting them to register their details if they wish to stand for their rights in the class action.
Next Steps for Interested Shareholders
Once shareholders register, they will receive updates and monitoring of the case's progress through portfolio software. This offers peace of mind to investors, ensuring that they remain informed throughout the legal proceedings without incurring any costs for participation.
Why Choose The Gross Law Firm?
The Gross Law Firm has established itself as a leading entity in handling class action lawsuits, particularly for those affected by misinformation and fraudulent practices. Their commitment to investor rights is reflected in their rigorous approach to holding companies accountable. They represent a wide array of investors looking to recover losses stemming from misleading statements or omissions that inflate stock values.
Contact Information
For specific inquiries or to learn more about participating in the class action, shareholders can reach out through the provided contact details. The Gross Law Firm is located at 15 West 38th Street, 12th Floor, New York, NY 10018. Interested parties can phone at (646) 453-8903 for further assistance.
Frequently Asked Questions
1. What is the purpose of this class action?
This class action aims to hold Actinium Pharmaceuticals accountable for any misleading information that may have affected shareholder investments.
2. How can I participate in the class action?
Shareholders can participate by registering their information with The Gross Law Firm before the deadline of May 27, 2025.
3. Do I need to be a lead plaintiff to join?
No, becoming a lead plaintiff is not mandatory for participation or potential recovery.
4. Is there a cost to participate in the class action?
No, there is no cost or obligation to join the class action.
5. How will I be updated on the case's progress?
Registered shareholders will receive updates via a portfolio monitoring system that tracks the case's developments.
